241 related articles for article (PubMed ID: 16337493)
1. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
2. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
3. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
4. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
5. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
6. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
7. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
8. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
Ogawa S; Takeuchi K; Ito S
Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
[TBL] [Abstract][Full Text] [Related]
9. Acarbose for patients with hypertension and impaired glucose tolerance.
Rosenthal JH
JAMA; 2003 Dec; 290(23):3066; author reply 3067-9. PubMed ID: 14679262
[No Abstract] [Full Text] [Related]
10. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
[No Abstract] [Full Text] [Related]
11. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
12. Acarbose for patients with hypertension and impaired glucose tolerance.
Bridges CM
JAMA; 2003 Dec; 290(23):3066-7; author reply 3067-9. PubMed ID: 14679261
[No Abstract] [Full Text] [Related]
13. Acarbose for patients with hypertension and impaired glucose tolerance.
Kaiser T; Sawicki PT
JAMA; 2003 Dec; 290(23):3066; author reply 3067-9. PubMed ID: 14679260
[No Abstract] [Full Text] [Related]
14. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes.
Breuer HW
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):421-40. PubMed ID: 14703948
[TBL] [Abstract][Full Text] [Related]
15. [Already in altered glucose tolerance an antidiabetic drug. Significantly fewer heart attacks].
MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619238
[No Abstract] [Full Text] [Related]
16. [Cardiovascular effects of oral hypoglycemie drugs].
Herrmann BL; Erbel R; Janssen OE; Mann K
Herz; 2004 Aug; 29(5):510-8. PubMed ID: 15340737
[TBL] [Abstract][Full Text] [Related]
17. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effective analysis of preventive treatment on diabetes].
Hu Y; Chen SY; Wang JY
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):431-4. PubMed ID: 15231174
[TBL] [Abstract][Full Text] [Related]
19. Prevention of type 2 diabetes.
Lai LC
Malays J Pathol; 2002 Dec; 24(2):71-6. PubMed ID: 12887163
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
